Is Function Health really worth $2.5B?

Why did Function Health become a $2.5 billion company?

Function Health reached a $2.5 billion valuation because its blood-testing membership grew extraordinarily fast, convincing investors that preventive healthcare could become a major consumer subscription business.

In November 2025, Andreessen Horowitz announced an oversubscribed $298 million Series B at that valuation. Function had launched its beta in 2023, so it took roughly two years to reach a price normally associated with much more established companies.

There was real commercial progress behind the fundraising. According to Sacra, Function reached approximately 200,000 members by May 2025, up from around 40,000 a year earlier. Sacra also estimated a $100 million annualized revenue run rate in February 2025, following approximately 450% year-over-year growth.

Investors were also betting on a much bigger business than blood testing. Function had acquired MRI-screening company Ezra, partnered with Quest Diagnostics for nationwide laboratory access, and started developing AI tools to explain medical results.

The $2.5 billion price reflected two things: a fast-growing business that already existed and a much larger healthcare platform that investors expected Function to build.

Is Function Health still worth $2.5 billion today?

Function Health's latest reported valuation is closer to $2.94 billion, roughly 18% above the $2.5 billion valuation announced in November 2025.

Forge Global records two additional Series B transactions dated July 30, 2026, totaling approximately $159.2 million. Both were associated with a $2.94 billion post-money valuation. Legion's private-company database independently reports a valuation of approximately $2.9 billion.

That is a meaningful increase in less than a year, although private-company valuations aren't continuously tested by public trading. The figures reflect financing transactions involving particular securities and terms, rather than a price at which every existing shareholder could necessarily sell.

Function also announced $450 million in growth financing from General Catalyst's Customer Value Fund in July 2026. This was a separate financing arrangement designed to support growth and customer acquisition, rather than another conventional priced equity round. The repayment economics weren't publicly disclosed.

Combining the $159.2 million equity transactions and $450 million growth facility shows how much capital investors and lenders were prepared to make available to Function. It would be incorrect, however, to add that financing directly to the company's valuation.

The latest private-market evidence supports a valuation above the original $2.5 billion headline. What it doesn't establish is how profitable Function has become.

Is Function Health still growing as fast as before?

Function Health's early growth was exceptional, but we can't confirm that the company is still adding members at the same pace today.

Sacra estimated that Function went from approximately 40,000 members in May 2024 to more than 200,000 in May 2025. That is at least fivefold growth in twelve months, representing roughly 160,000 additional members.

On average, Function added more than 13,000 net members per month over that period. For a subscription requiring customers to pay hundreds of dollars out of pocket for preventive testing, that was a substantial achievement.

More recent activity figures suggest the company has continued expanding. Function's November 2025 announcement referenced more than 50 million laboratory results delivered since launch. Its current membership website reports more than 75 million results delivered.

That represents at least another 25 million cumulative results, or a 50% increase over the earlier benchmark. However, each member generates many individual test results, so these totals cannot tell us how many new people subscribed.

The missing figure is Function's current active paying-member count. Without that, we cannot calculate its latest annual membership growth or determine whether the extraordinary 2024–2025 pace has continued.

Is Function Health making enough money to justify $2.5 billion?

Function Health's last widely reported revenue estimate was impressive for such a young company, but still small relative to a $2.5 billion valuation.

Sacra estimated a $100 million annualized revenue run rate in February 2025. At that level, investors were valuing Function at roughly 25 times annualized revenue. For comparison, a business generating $500 million annually would be valued at five times revenue under the same $2.5 billion price.

There are two important qualifications. Sacra's figure was an estimated run rate, rather than audited full-year revenue. And Function's membership price subsequently fell from $499 to $365, meaning member growth no longer translates into subscription revenue at the same rate.

We also lack a verified current revenue breakdown between memberships, imaging, additional testing, and other services. That prevents us from calculating a reliable up-to-date revenue multiple.

The scale of the challenge is nevertheless clear. Function would need to reach approximately $250 million in annual revenue for its $2.5 billion valuation to equal 10 times sales. At $500 million, the multiple would fall to five.

Those levels are possible for a national consumer healthcare business. But until Function provides more recent financial numbers, investors are paying a substantial premium for growth they expect to see rather than revenue they can already verify.

If you want more recent data on this point, please see our latest digital health market report.

How many customers would Function Health need to justify $2.5 billion?

Function Health would need roughly 685,000 full-price annual memberships to generate $250 million in subscription revenue at its current $365 price.

That is more than three times Sacra's May 2025 estimate of approximately 200,000 members. A $500 million subscription business would require around 1.37 million paying members.

The numbers also reveal why additional services matter. At 1 million members, the standard subscription would generate $365 million annually before discounts, refunds, and other adjustments. An extra $135 in average annual revenue per member would bring the business to $500 million.

Function could theoretically generate that additional spending through imaging, extra tests, or other health services. But an MRI purchase involves considerably higher delivery costs than an additional software feature, so the type of revenue matters.

The table below shows the size of the membership base needed at different annual revenue levels. It assumes every member pays the full $365 for the year and excludes all other products.

Annual membership revenue	Members needed	$2.5B valuation / revenue
$50M	137,000	50.0x
$75M	205,000	33.3x
$100M	274,000	25.0x
$150M	411,000	16.7x
$200M	548,000	12.5x
$250M	685,000	10.0x
$350M	959,000	7.1x
$500M	1.37M	5.0x

Why did Function Health cut its subscription from $499 to $365?

Function Health lowered its annual subscription price by 26.9% in November 2025, making the service more accessible while raising the number of customers needed to generate the same revenue.

The arithmetic is straightforward. At $499, 200,000 memberships would generate $99.8 million in annual subscription billings. At $365, the same number would generate $73 million.

Function therefore needs approximately 36.7% more full-price members to recover the revenue lost through the price cut, assuming nothing else changes.

The company was clearly willing to sacrifice some revenue per subscription to reach more consumers. Its new price can be marketed as $1 per day, which makes the product easier to understand and potentially easier to sell.

There is evidence of further price experimentation. During its Function Day promotion in October 2026, new members could subscribe for $295 for their first year, approximately 19% below the standard $365 price. Existing members and renewals remained subject to the regular price.

We don't know how much these changes improved conversions or customer-acquisition costs. But the price cuts suggest Function is actively testing how far it can broaden demand.

The strategy could work extremely well if lower prices produce much faster growth. It becomes expensive if customers require large discounts to subscribe and then fail to renew.

Is Function Health's $365 membership actually worth the money?

Function Health's $365 membership is competitively priced for the amount of testing included, although the medical usefulness of that testing depends heavily on the individual.

Members receive more than 160 laboratory tests across an annual baseline and a mid-year follow-up. Results include clinician review, personalized explanations, and recommendations. Testing is available through more than 2,000 Quest Diagnostics locations in the United States, with optional at-home blood collection for an additional charge.

The package covers cardiovascular health, metabolism, thyroid function, hormones, nutrients, inflammation, liver function, and several other categories.

Buying the same collection of tests individually at retail prices could be considerably more expensive. Function's website says comparable testing could cost as much as $15,000, although that promotional comparison shouldn't be interpreted as what a typical patient would otherwise spend.

Many routine blood tests are already covered by insurance when a doctor considers them medically necessary. And people who are generally healthy may not benefit from measuring every available biomarker repeatedly.

The most compelling part of Function's offer is the combination of broad access, predictable pricing, and results that can be compared over time. For consumers who actively want comprehensive testing without navigating insurance approvals, $365 can be a good deal.

Whether it improves their health enough to justify renewing every year is another question. A long list of test results can feel valuable even when relatively few of them lead to useful medical decisions.

If you want more recent data on this point, please see our latest digital health market report.

Will Function Health's customers really renew every year?

Function Health has a good reason for people to subscribe again, but its actual renewal rates remain undisclosed.

Unlike a one-time medical test, Function's membership encourages customers to establish a baseline, make changes, and measure their results again. Someone who discovers elevated ApoB, abnormal blood glucose, or a nutrient deficiency may want to see whether those markers improve after changing treatment, diet, or exercise.

Function's annual and mid-year testing schedule supports that habit. As members accumulate several years of results, their personal medical history also becomes more useful.

But there is another likely customer behavior: subscribe once, complete the tests, receive reassuring results, and cancel.

The financial difference is enormous. At 70% annual retention, approximately 49% of an original cohort remains after two renewals. At 90% retention, roughly 81% remains.

Those are illustrative scenarios, not Function's reported rates. The company has not published the cohort data needed to calculate its actual retention.

Given the $2.5 billion valuation, this may be the single most important missing operating metric. Strong renewals would allow Function to keep growing without constantly replacing departing customers. Weak renewals could turn an attractive-looking membership business into an expensive cycle of customer acquisition.

Is Function Health profitable yet?

Function Health has not publicly demonstrated that it is profitable, and its business involves more operating costs than a typical software subscription.

The company hasn't published a full income statement showing gross profit, operating income, or net profit. We therefore cannot calculate how much money it currently makes or loses on a $365 membership.

Function works with independent laboratory and medical providers. Its membership includes laboratory testing, clinician-reviewed results, digital infrastructure, support, and personalized insights. Marketing, compliance, and product development add further expenses.

There is a useful comparison with Quest Diagnostics, one of Function's partners. Quest reported approximately $11.04 billion in revenue and $1.56 billion in operating income for 2025, giving it a 14.1% operating margin.

Quest runs a fundamentally different business, so that margin cannot simply be assigned to Function. But it reminds us that laboratory services involve real delivery costs.

We can calculate what Function would need to earn under different hypothetical scenarios. At $500 million in revenue and a 25% operating margin, it would generate $125 million in operating profit. That would put its $2.5 billion valuation at 20 times operating earnings.

At $250 million in revenue and a 15% operating margin, the same valuation would represent nearly 67 times operating profit.

Function's actual margins could be higher or lower. Until the company publishes financial results, these scenarios are useful benchmarks rather than forecasts.

Annual revenue	Operating margin	Operating profit	Valuation / operating profit
$150M	10%	$15M	166.7x
$200M	15%	$30M	83.3x
$250M	15%	$37.5M	66.7x
$300M	20%	$60M	41.7x
$400M	20%	$80M	31.3x
$500M	15%	$75M	33.3x
$500M	25%	$125M	20.0x
$750M	25%	$187.5M	13.3x

Is Superpower becoming a serious threat to Function Health?

Superpower is a credible competitor to Function Health because it offers comprehensive blood testing at comparable or lower prices, putting pressure on one of Function's biggest selling points.

Superpower has advertised a $199 annual option covering more than 100 biomarkers, alongside a $349 option with more than 150 biomarkers and repeat testing. At $199, its entry offer is approximately 45% cheaper than Function's standard $365 membership, although the testing schedules and included services differ.

Both companies use established laboratory infrastructure and provide digital explanations of test results. Neither needs to build an entirely new nationwide network of laboratories to offer consumer blood testing.

Competition also comes from companies serving overlapping needs. InsideTracker focuses on biomarker analysis and lifestyle recommendations. Prenuvo offers advanced body imaging. Traditional laboratories and telehealth providers offer many of the individual tests customers might otherwise purchase through Function.

Function's broader product experience is currently a differentiator. Its combination of repeated blood testing, imaging access, clinician-reviewed reports, and personalized recommendations gives customers several reasons to stay within one service.

Still, the core testing offer is fairly easy to compare by price and included biomarkers. Function's original $499 membership has already fallen to $365, and newer promotional pricing shows that the company is willing to compete on affordability.

If consumers eventually see comprehensive testing as a standardized service, Function will have to earn its premium through convenience, interpretation, and trust. That's a tougher business to defend than simply offering more biomarkers than everyone else.

If you want more recent data on this point, please see our latest digital health market report.

Did buying Ezra make Function Health a stronger business?

Function Health's acquisition of Ezra in May 2025 significantly strengthened its product offering by adding MRI screening to its existing blood-testing membership.

Ezra had developed AI-assisted imaging technology aimed at reducing scanning times and costs. When announcing the acquisition, Function highlighted an MRI offering starting at $499, compared with Ezra's previous pricing around $1,500, and technology that could shorten certain scan times from roughly 60 minutes to 22 minutes.

The company's current membership materials advertise advanced MRI access from $899, so the original $499 launch price should not be treated as the standard price available today.

The commercial opportunity is substantial. A Function member paying $365 annually for blood testing may also purchase imaging, increasing total spending without requiring Function to acquire another subscriber.

Imaging also makes Function more relevant to customers who want a broader assessment of their health. It can connect laboratory findings with information from scans, although combining those services doesn't automatically improve clinical outcomes.

The challenge is profitability. MRI services require imaging facilities, equipment, specialists, and clinical interpretation. Revenue from a $899 scan cannot be compared directly with revenue from a digital subscription.

Function has not disclosed Ezra's post-acquisition revenue, scan volume, or gross margin. The acquisition clearly broadened the business, but its financial contribution remains difficult to measure.

Is Function Health building something competitors can't easily copy?

Function Health is building a broader healthcare service that could become difficult to replace, although its advantage currently comes more from integration and customer relationships than exclusive technology.

The company's acquisitions show a consistent direction.

Ezra brought medical imaging in 2025. In 2026, Function added SuppCo, a supplement-tracking platform, and Getlabs' nationwide at-home and office blood-draw network. Its partnership work also includes Google Health integrations intended to connect laboratory results with information from wearable devices.

Each addition addresses another part of the same experience. Customers can arrange testing, receive results, consider changes to their routines, track supplements, and eventually compare new measurements with previous ones.

This is a more useful foundation than simply selling large blood panels. The longer someone uses Function, the more health information the platform can organize in one place.

There are limits to that advantage. Customers can obtain laboratory tests through Quest, imaging through independent providers, and medical advice from their own clinicians. Software competitors can also develop similar dashboards and AI tools.

Function's best opportunity is to make that combination convenient enough that customers prefer staying in one ecosystem. The acquisition strategy makes sense, but we haven't seen retention data proving the ecosystem already creates strong customer loyalty.

Can Function Health become a major AI healthcare company?

Function Health has enough medical data and customer activity to build useful personalized AI tools, but there is no public evidence that AI is already a major source of its revenue.

In November 2025, Function introduced its Medical Intelligence Lab, private AI chat, and personalized protocols. These tools are designed to explain laboratory results and recommend possible changes involving nutrition, exercise, supplements, sleep, and other habits.

Function's reported 75 million-plus laboratory results provide a substantial information base. But that number counts individual results, rather than unique patients, and doesn't establish the accuracy of an AI model.

The potential advantage comes from context. A general chatbot can explain what elevated cholesterol means. Function's tools can potentially interpret someone's actual cholesterol results alongside their previous measurements, metabolic markers, reported medical history, and wearable-device information.

That could make personalized health guidance much more useful, particularly when people return for testing repeatedly.

However, Function describes itself as a healthcare technology company rather than a medical provider. Its laboratory and medical services are delivered by independent third parties, and the platform states that it does not itself provide medical diagnosis or treatment.

There is also a gap between generating personalized recommendations and proving that those recommendations improve patients' health. Published comparative clinical results would help establish that value.

AI could become central to Function's product experience. For now, assigning it a large standalone financial value would be premature.

Does Function Health's extensive testing actually make people healthier?

Function Health makes preventive testing considerably easier to access, but there is no clear evidence that measuring more than 160 biomarkers automatically improves health outcomes for most customers.

Some preventive tests have strong clinical support. Screening for diabetes, certain cancers, cardiovascular risk factors, and other conditions can be valuable when performed in the right populations.

Other tests are less useful when offered broadly to people without symptoms or particular risk factors. Abnormal findings can lead to unnecessary investigations, anxiety, and medical expenses.

The debate is especially relevant to whole-body MRI screening. In April 2023, the American College of Radiology stated that there wasn't enough evidence to recommend total-body MRI screening for asymptomatic people without relevant risk factors or family history.

Research has shown that such scans can detect previously unknown abnormalities, including some cancers. However, detection rates, incidental findings, unnecessary follow-up, and whether screening improves survival must all be considered together.

Function's value proposition is strongest when testing leads to an actionable medical decision. Discovering an elevated cardiovascular risk marker and discussing appropriate treatment with a clinician is different from finding an ambiguous abnormality that requires several additional scans.

We should also distinguish customer satisfaction from medical effectiveness. People may genuinely value having more information about their bodies even when a particular test hasn't been shown to improve long-term outcomes.

Function can build a successful consumer business around that demand. But if it wants to become an important healthcare company over the long term, demonstrating better health decisions will matter increasingly.

If you want more recent data on this point, please see our latest digital health market report.

Is Function Health worth more than a traditional diagnostics company?

Function Health deserves to be valued differently from traditional laboratories only if its customer relationships and digital services eventually produce better growth or margins.

Quest Diagnostics illustrates the difference. Quest generated approximately $11.04 billion in annual revenue in 2025 and reported $1.56 billion in operating income. Its business depends on processing medical tests at scale for healthcare providers, employers, and consumers.

Function sits closer to the consumer. It packages testing into a recurring membership, organizes results, and offers access to related services. This gives Function more control over the customer experience, but the company still depends heavily on outside providers to deliver medical services.

The economic distinction becomes important as Function grows.

If it mainly resells testing with a relatively small margin, investors should judge it partly on the economics of diagnostic services. If it can retain members for years and sell profitable additional services through the same relationship, its revenue could become more valuable.

The $2.5 billion valuation clearly assumes the second model will develop.

That isn't an unreasonable assumption, given Function's early adoption and acquisitions. But the company hasn't yet demonstrated that its margins, renewal rates, or additional spending resemble those of a highly profitable digital platform.

What would make Function Health worth $5 billion?

Function Health could support a $5 billion valuation if it becomes a business generating several hundred million dollars in recurring annual revenue with attractive profits, although the required scale depends on how quickly it continues growing.

At the standard $365 membership price, 1 million full-price annual subscribers would generate $365 million in subscription billings. With 2 million subscribers, that figure would reach $730 million.

Additional services could increase the totals. If 1 million members generated an average of $500 each across membership fees and other purchases, Function would reach $500 million in annual revenue. At 2 million members, the same spending level would produce $1 billion.

Under those scenarios, a $5 billion valuation would represent 10 times revenue at $500 million, or five times revenue at $1 billion.

The second scenario is much easier to defend financially, especially if Function can demonstrate positive operating margins and strong membership retention.

Its product expansion gives it several ways to pursue those numbers. MRI screening increases potential spending per customer, Getlabs can make blood testing more convenient, and AI-assisted interpretation may improve continued engagement. Partnerships could also bring new customers without relying entirely on direct advertising.

The problem is the distance from the last independently reported membership count. Going from approximately 200,000 members to 2 million would represent a tenfold increase.

Function has already shown it can grow unusually fast. Reaching several million paying customers while maintaining good economics would be a different achievement altogether.

What could cut Function Health's valuation in half?

Function Health's valuation could fall sharply if customer growth slows and the company struggles to turn its subscriptions into meaningful profit.

At a $1.25 billion valuation, Function would still be worth approximately 12.5 times the $100 million annualized revenue run rate Sacra estimated in early 2025. Even a 50% valuation decline wouldn't necessarily imply that the underlying business had failed.

The most obvious threat is price competition. Superpower and other providers are making broad blood panels cheaper, while existing laboratories already handle much of the technical work involved. Function could face pressure to reduce prices further or spend more on marketing.

Weak customer retention would make that pressure worse. A member who pays $365 once and cancels after receiving normal results has a very different financial value from someone who renews for five years.

Expansion could also disappoint. Imaging generates higher transaction amounts but comes with significant service costs. AI features may improve the experience without producing enough extra revenue to change the business's profitability.

There is a separate risk around medical credibility. If comprehensive screening produces too many unnecessary follow-ups or fails to show clear clinical benefits, Function may struggle to expand beyond consumers already enthusiastic about preventive health.

The company has substantial financing and an established customer base, so a severe decline in valuation wouldn't necessarily mean imminent financial distress. But investors are expecting Function to become much larger than it is today. Missing those expectations could be costly.

Is Function Health really worth $2.5 billion?

Yes, Function Health's $2.5 billion valuation is defensible today, but the company has yet to prove that its financial performance fully supports that price.

The strongest evidence is its early commercial growth. Function increased its estimated membership approximately fivefold in one year, reached a reported $100 million annualized revenue run rate, and built a nationally available service around a $365 annual subscription.

It has also moved well beyond its original testing product. The acquisitions of Ezra, Getlabs, and SuppCo, alongside its work in AI-assisted interpretation, give Function a credible opportunity to earn more from each customer and build longer-lasting relationships.

Investors have continued supporting that strategy. The original $298 million Series B valued Function at $2.5 billion, while subsequent private-market transactions suggest a valuation closer to $2.94 billion.

Still, we are missing several numbers that would make the financial case much stronger: current paying members, annual revenue, customer retention, gross margins, and operating profitability.

Without those figures, we cannot establish whether Function's valuation reflects an already profitable business or mainly the expectation that it will become one.

Our conclusion is that $2.5 billion is a plausible price for Function's growth and future potential, but a demanding one relative to what has been publicly verified. Reaching $500 million in annual revenue with credible operating profits would make the valuation considerably more convincing.

Function has already proved that a large number of consumers will pay directly for comprehensive preventive testing. Its next challenge is to prove that those consumers will keep paying, use more of its services, and generate enough profit to justify a multibillion-dollar company.

If you want more recent data on this point, please see our latest digital health market report.